Atrasentan: Phase III data

A meta-analysis of 1,097 patients in 2 Phase III studies (M96-594 and M00-211) showed that 2.5 and 10 µg doses of atrasentan significantly delayed time to disease progression vs. placebo (p=0.014). Ho...